Clinical Trial Update: A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AbGn-168H for steroid-refractory acute graft-versus-host disease after donor stem cell transplant has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• AbGn-168H

Snippet

Sponsor: AbGenomics B.V Taiwan Branch | Conditions: Acute Graft Versus Host Disease | Phase 1 | Status: TERMINATED